Novo Nordisk takes PADE reporting requirements seriously and we plan to address the requests in the Warning Letter expeditiously and holistically, the statement read, referring to safety reports sent to the FDA after a drug's approval.
Always consult a professional for medical advice
World Journal of Gastroenterology
Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)
at which points there were 102 subjects), a cohort study published in JAMA Network Open in 2022 found